Key Highlights
- 4D Molecular Therapeutics shares traded at $11.09, up 0.91% on the day.
- Two-year Phase 2b PRISM data was shared at ASRS.
- A single dose of 4D-150 delivered a 78% reduction in overall treatment burden, rising to 87% in recently diagnosed patients.
- The data also showed maintained visual acuity and retinal anatomic control.
4D Molecular Therapeutics Inc. (NASDAQ: FDMT) shares traded at $11.09, up 0.91% on the day, after the company shared two-year Phase 2b PRISM trial data for 4D-150 in wet age-related macular degeneration (AMD) at the ASRS meeting.
What Happened
The data, noted July 18, 2026, demonstrated that a single dose of 4D-150 maintained visual acuity and retinal anatomic control while delivering a 78% reduction in overall treatment burden.
That reduction in treatment burden increased to 87% in recently diagnosed patients, according to the disclosed information.
Market Reaction
Shares rose modestly, up 0.91% to $11.09, with 4D Molecular Therapeutics' market capitalization at approximately $579.74 million, according to the disclosed pipeline database.
The relatively modest share price move contrasts with the scale of the reported treatment burden reduction, which could represent a meaningful differentiator for a single-dose gene therapy in a disease that typically requires frequent ongoing injections.
Outlook
The disclosed information does not include a specific timeline for further trial phases or regulatory submissions for 4D-150 in wet AMD beyond the reported two-year PRISM data.
What did 4D Molecular Therapeutics' two-year PRISM data show?
A single dose of 4D-150 maintained visual acuity and retinal anatomic control while reducing overall treatment burden by 78%, rising to 87% in recently diagnosed patients.
What condition is 4D-150 being developed to treat?
4D-150 is being developed as a gene therapy for wet age-related macular degeneration (AMD).
Where was this data presented?
The data was shared at the ASRS meeting, noted July 18, 2026.






Please wait processing your request...